Klin Farmakol Farm. 2012;26(2):61-66

Resistance of Enterobacteriaceae to selected antibiotics in relation to their consumption

Miroslava Htoutou Sedláková1, Vladimíra Vojtová2, Vojtěch Hanulík1, Hana Suchánková2, Milan Kolář1
1 Ústav mikrobiologie LF UP v Olomouci a FN Olomouc
2 Ústav klinické farmakologie LF UP v Olomouci

The aim of the present study was to analyse the development of resistance of clinically most relevant Enterobacteriaceae in association with

the selection pressure of selected antibiotic groups. We evaluated the development of resistance of K. pneumoniae (a total of 31,627 strains),

E. coli (55,727 strains), E. cloacae (3,251 strains) and P. mirabilis (13,751 strains) in relation to the consumption of third- and fourth-generation

cephalosporins, fluoroquinolones, and piperacilin/tazobactam at the Olomouc University Hospital in the years 2000 to 2010. The resistance

of Enterobacteriaceae to piperacillin/tazobactam was found to increase depending on the consumption of this antibiotic. By contrast, their

resistance to third- and fourth-generation cephalosporins and fluoroquinolones increases despite a reduction in their consumption. The

resistance of Enterobacteriaceae to these antibiotics is likely to be so significant that even a reduction in their consumption has not resulted

in its decrease. The possibility has to be taken into account that the selection pressure of antibiotics, as a factor of spread of bacterial resistance,

has moved to the background, and recombinant processes and transferable genetic elements are beginning to play the major role.

Keywords: resistance, Enterobacteriaceae, antibiotics, fluoroquinolones, cefalosporins, piperacillin/tazobactam, selection pressure

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Htoutou Sedláková M, Vojtová V, Hanulík V, Suchánková H, Kolář M. Resistance of Enterobacteriaceae to selected antibiotics in relation to their consumption. Klin Farmakol Farm. 2012;26(2):61-66.
Download citation

References

  1. Abraham EP, Chain E. An enyzme from bacteria able to destroy penicillin. Nature 1940; 146: 837. Go to original source...
  2. Abraham EP, Gardner AD, Chain E, Fletcher CM, Florey HW, Heatley NG, et al. Further observations on penicillin. Lancet 1941; 2: 6155-6166. Go to original source...
  3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for ?-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233. Go to original source... Go to PubMed...
  4. Ambler RP, Meadway RJ. Chemical structure of bacterial penicillinases. Nature 1969; 222: 24-26. Go to original source... Go to PubMed...
  5. Jacoby GA, Bush K. Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant ?-lactamases. 2009; available from: http://www.lahey.org/Studies/.
  6. Bush K, Jacoby GA. An updated functional classification of ?-lactamases. Antimicrob Agents Chemother 2010; 54: 969-976. Go to original source... Go to PubMed...
  7. Bradford PA. Extended-spectrum ?-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951. Go to original source... Go to PubMed...
  8. Hanulík V, Htoutou-Sedláková M, Petrželová J, Kolář M. Možnosti fluorochinolonů v současné praxi. Klin Farmakol Farm 2010; 24: 184-186.
  9. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Available from: http://www.eucast.org/clinical_breakpoints.
  10. Htoutou-Sedlakova M, Hanulik V, Chroma M, et al. Phenotypic detection of broad-spectrum beta-lactamases in microbiological practice. Med Sci Monit 2011; 17: 147-152. Go to original source... Go to PubMed...
  11. Chroma M, Kolar M. Genetic methods for detection of antibiotic resistance: focus on extended-spectrum ?-lactamases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154: 289-296. Go to original source... Go to PubMed...
  12. Anatomical therapeutic chemical (ATC) index (including defined daily doses (DDDs) for plain substances) Oslo: WHO collaboration centre for drug statistics methodology, 1996.
  13. Bergman U, Christerson I, Jansson B, Wiholm BE. Auditing drug utilization by means of defined daily dose per bed-day. A methodological study. Eur J Clin Pharmacol 1980; 17: 183-187. Go to original source... Go to PubMed...
  14. Kolář M, Látal T, Čermák P, et al. Prevalence of extended-spectrum beta-lactamase-positive Klebsiella pneumoniae isolates in the Czech Republic. Intern J Antimicrob Agents 2006; 28: 49-53. Go to original source... Go to PubMed...
  15. Htoutou Sedláková M, Hanulík V, Chromá M, et al. Rezistence enterobakterií ke karbapenemům. Klin Mikrobiol Inf Lék 2011; 17: 12-18.
  16. Rahal JJ, Urban C, Horn D. Class restriction of cephalosporin use to control total cephalosporin resistance in nozocomial Klebsiella. JAMA 1998; 280: 1233-1237. Go to original source... Go to PubMed...
  17. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents. 2001; 17: 357-363. Go to original source... Go to PubMed...
  18. Urbánek K, Kolář M, Lovečková Y, Strojil J, Šantavá L. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. Journal of Clinical Pharmacy and Therapeutics 2007; 32: 403-408. Go to original source... Go to PubMed...
  19. Haller P, Tschudin S, Dangel M. Increase of resistant Enterobacter isolates and correlation with antibiotic consumption at the ward level. Poster presented in 16. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, 1.-4. April. Poster available online from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=17620&XNSPRACHE_ID=2&XNKONGRESS_ID=26&XNMASKEN_ID=900.
  20. Asensio A, Alvarez-Espejo T, Fernandes-Crehuet J, et al. On behalf of the Estudio de Prevalencia de las Infecciones Nosocomiales en Espańa (EPINE) Working Group. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Euro Surveill. 2011; 16(40): pii=19983. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19983. Go to original source... Go to PubMed...
  21. Bosso JA, Mauldin PD, Salgado CD. The association between antibiotic use and resistance: the role of secondary antibiotics. Eur J Clin Microbiol Infect Dis 2010; 29: 1125-1129. Go to original source... Go to PubMed...
  22. Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-458. Go to original source... Go to PubMed...
  23. Rice LB, Eckstein EC, DeVente J, et al. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-124. Go to original source... Go to PubMed...
  24. Pettrikos G, Markogiannakis A, Papapareskevas J, et al. Differences in the changes in resistance patterns to thirdand fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital. Int J Antimicrob Agents. 2007; 29: 34-38. Go to original source... Go to PubMed...
  25. Piroth L, Aube H, Doise JM, et al. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998; 27: 76-80. Go to original source... Go to PubMed...
  26. Meyer E, Lapatschek M, Bechtold A, Schwarzkopf G, Gastmeier P, Schwab F. Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. Int Care Med. 2009; 35: 862-870. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.